As a therapeutic target, anti-CD47 antibody has shown promising results in diffuse large B-cell lymphoma, pediatric malignant brain tumor, ovarian cancer, hepatocellular carcinoma, and lung cancer [16,17,18,19,20]. This evidence concerns the gene CD47 and hepatocellular carcinoma.